Clinical Trials
Enrolling Trials
71-80 of 168
CIRB, Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Genitourinary
Adult
To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in patients with CRPC that have previously received docetaxel and ADT for HSPC can improve PFS compared to abiraterone acetate alone.
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
MMC - Eau Claire
2310 Craig Rd
Eau Claire, WI 54701
MMC - Ladysmith
906 College Ave W
Ladysmith, WI 54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9576 Highway 70
MINOCQUA, WI 54548
MMC - River Region at Stevens Point
4100 State Highway 66
Stevens Point, WI 54482
MMC - Weston
3400 Ministry Parkway
WESTON, WI 54476
zzzRice Clinic Medical Center
2501 Main
Stevens Point, WI 54481
CIRB, A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL)
Leukemia
Adult
This phase II Lung-MAP non-Match treatment trial studies how well ramucirumab and pembrolizumab work versus standard of care in treating patients with non-small cell lung cancer that is stage IV or has come back. Immunotherapy with monoclonal antibodies, such as ramucirumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in standard of care chemotherapy for non-small cell lung cancer, such as docetaxel, gemcitabine hydrochloride, and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ramucirumab and pembrolizumab together may work better in treating patients with non-small lung cancer compared to standard of care.
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9576 Highway 70
MINOCQUA, WI 54548
MMC - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - River Region at Stevens Point
4100 State Highway 66
Stevens Point, WI 54482
MMC - Weston
3400 Ministry Parkway
WESTON, WI 54476
CIRB, A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
Hematology
Adult
This phase III trial studies how well ibrutinib and obinutuzumab with or without venetoclax work in treating patients with chronic lymphocytic leukemia. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib, obinutuzumab and venetoclax may work better in treating patients with chronic lymphocytic leukemia.
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Ladysmith
906 College Ave W
Ladysmith, WI 54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9576 Highway 70
MINOCQUA, WI 54548
MMC - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - River Region at Stevens Point
4100 State Highway 66
Stevens Point, WI 54482
MMC - Weston
3400 Ministry Parkway
WESTON, WI 54476
CIRB, Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Leukemia
Adult
This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of minimal residual disease, defined as the levels of a gene product called bcr-abl in the blood. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Dasatinib, imatinib mesylate, and nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and dasatinib, imatinib mesylate, or nilotinib may work better in treating patients with chronic myeloid leukemia.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
CIRB, Longitudinal Assessment of Financial Burden in Patients with Colon or Rectal Cancer Treated with Curative Intent
Cancer Symptom Management
Adult
Evaluate the change in level of self-reported financial burden from baseline (within 60 days of diagnosis) to 12 months after diagnosis of colon or rectal cancer treated with curative-intent.
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
MMC - Eau Claire
2310 Craig Rd
Eau Claire, WI 54701
MMC - Ladysmith
906 College Ave W
Ladysmith, WI 54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9576 Highway 70
MINOCQUA, WI 54548
MMC - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - River Region at Stevens Point
4100 State Highway 66
Stevens Point, WI 54482
MMC - Weston
3400 Ministry Parkway
WESTON, WI 54476
CIRB, Molecular Analysis for Therapy Choice (MATCH)
Miscellaneous Neoplasm
Adult
This randomized phase I/II trial studies the side effects and best dose of pomalidomide and ixazomib when given together with dexamethasone and to see how well pomalidomide and dexamethasone with or without ixazomib works in treating patients with multiple myeloma that has come back. Biological therapies, such as pomalidomide and dexamethasone, may stimulate the immune system in different ways and stop cancer cells from growing. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether pomalidomide and dexamethasone are more effective with or without ixazomib in treating multiple myeloma.
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
MMC - Ladysmith
906 College Ave W
Ladysmith, WI 54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9576 Highway 70
MINOCQUA, WI 54548
MMC - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - River Region at Stevens Point
4100 State Highway 66
Stevens Point, WI 54482
MMC - Weston
3400 Ministry Parkway
WESTON, WI 54476
zzzDiagnostic & Treatment Center
3401 CRANBERRY BLVD
WESTON, WI 54476
zzzLakeview Medical Center
1700 West Stout Street
Rice Lake, WI 54868
zzzMarshfield Medical Center
611 Saint Joseph Ave
Marshfield, WI 54449
zzzMfld Clinic Cancer Care at Sacred Heart Hospita
900 W CLAIREMONT AVE
EAU CLAIRE, WI 54701
zzzSacred Heart Hospital (Eau Claire)
900 W Clairemont Ave
Eau Claire, WI 54701
zzzSt. Michaels Hospital
900 Illinois Ave
Stevens Point, WI 54481
CIRB, MATCH Treatment Subprotocol Z1G: Phase 2 STudy of Copanlisib in Patients with Tumors with PTEN Loss by IHC and Any PTEN Sequencing Result
Mutations
Adult
The purpose of this study is to test any good and bad effects of the study drug copanlisib in patients whose cancer has PTEN loss. Copanlisib could shrink your cancer if your tumor has PTEN loss but it could also cause side effects.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
CIRB, MATCH Treatment Subprotocol Z1H: Phase 2 STudy of Copanlisib in Patients with Tumors with Deleterious PTEN Sequencing Result and PTEN Expression by IHC
Mutations
Adult
The purpose of this study is to test any good and bad effects of the study drug copanlisib in patients whose cancer has PTEN loss. Copanlisib could shrink your cancer but it could also cause side effects. Researchers hope to learn if the study drug will shrink the cancer by at least one-quarter compared to its present size.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
CIRB, MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
Mutations
Adult
This phase III trial studies how well gemcitabine hydrochloride and cisplatin given with or without nab-paclitaxel work in treating patients with newly diagnosed biliary tract cancers that have spread to other places in the body. Drugs used in chemotherapy, such as gemcitabine hydrochloride, cisplatin, and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not known if giving gemcitabine hydrochloride and cisplatin with or without nab-paclitaxel may work better at treating biliary tract cancers.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
CIRB, MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
Mutations
Adult
N/A
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449